Spectrum Pharmaceuticals (NASDAQ:SPPI) announces
a publication entitled, “Pan-Cancer Landscape and Functional Analysis
of ERBB2 Mutations Identifies Poziotinib as a Clinically Active
Inhibitor and Enhancer of T-DM1 Activity.”
In Company’s pre-clinical study of 11 EGFR/HER2
tyrosine kinase inhibitors, poziotinib was the most potent HER2
mutant-selective TKI tested, and was found to be highly active in NSCLC
patients with HER2 exon 20 mutations.
Poziotinib is found to be synergistic with a
HER2-targeting antibody-drug conjugate, providing a rationale for
combinations to move forward into the clinic.
The Company plans to disclose topline data from
the first cohort of ZENITH20 study in current quarter. Topline data from
cohort 2 is expected by mid-2020.
Spectrum received exclusive license from Hanmi
Pharmaceuticals to develop and commercialize poziotinib worldwide,
excluding Korea and China.
Shares are up 2% premarket.
https://seekingalpha.com/news/3503957-spectrum-pharma-announces-publication-positive-poziotinib-data-cancer-cell
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.